Undermining Future Drug Innovation

 

Just when you thought the value of a robust pharmaceutical industry couldn’t be more obvious, politicians now want to “kill the goose that laid the golden egg.” A year ago, we were desperate for a new vaccine to protect us from the Covid-19 scourge, and now some want to undermine the system that brought us vaccines in record time.

The Wall Street Journal editorial board puts it this way: “It’s one of the strangest, and most destructive, juxtapositions in political history. Even as vaccines are saving the world from Covid, the Democratic Party wants to rob these firms of the reward for innovation that is essential to developing future cures.”

The backstory on this fiasco is that Democrats are scrambling to pay for their massive $3.5 Trillion (or more) expansion of the entitlement state. Even taxing the rich even more (the top 1% pay 40% of all taxes) will only find $2.2 Trillion of new revenue, so they’re desperate to find more. They believe they can fill the gap with $500 billion in savings from price controls on drugs.

Democrats claim the bill would simply allow Medicare to “negotiate” what they deem “fair” prices as foreign governments with national healthcare systems do. The bill sets a price ceiling of 120% of the average drug price in Australia, Canada, France, Germany, Japan and the U.K. The HHS secretary could decide to pay less.

The bill directs HHS to focus on the 250 most expensive and common brand-name drugs without generic competitors. The secretary would be required to “negotiate” at least 25 drugs in the first year of the program (2025) and 50 in future years. If companies refuse the government’s price, they must pay a 95% excise tax on all revenue they generate from that drug in the U.S. They would also have to offer the government price to private insurers. This can hardly be described as a “negotiation” when the government is pointing a gun at their heads.

To analyze the impact of such legislation, the Journal of the American Medical Association (JAMA) published a study that estimates drug spending in the U.S. would have been 52%, or about $83.5 billion, less in 2020 based on the bill’s formula. The research company Vital Transformation estimates the bill would reduce bio-pharmaceutical earnings by $102 billion a year.

If you’re like most people, you think pharmaceutical companies can easily afford such cuts in their revenue and the public will never notice the difference. But consider that major pharmaceutical companies invested $91 billion in research and development in 2020. In other words, Democrats would be confiscating nearly all the profits companies use to finance their clinical research. Simply put – no profits, no research, no new drugs. No new vaccines when the world is desperate to fight the next pandemic.

WSJ says, “This tax on innovation would damage big pharma companies like Pfizer and Merck, but it would be a death blow to small biotech firms where many breakthroughs originate.” How important are these smaller biotech firms? Biotech startups patented nearly two-thirds of new drugs in 2018, and in their early stages they rely almost entirely on venture capital. Later they often cooperate with or license their discoveries to large drug makers. Only about 15% of drugs and vaccines that enter clinical trials are approved. The rate for oncology therapies is only 3%.

Most people think the new Covid vaccines were developed just since the start of the Covid pandemic. But these hugely successful mRNA Covid vaccines are the result of approximately ten years of study and billions of dollars invested in that research. Without this kind of R & D, there will be no new vaccines the next time a new virus emerges.

The bill would “immediately have the effect of putting many early-stage biotech companies out of business,” says Strand Therapeutics CEO Jake Becraft. He adds that Moderna would never have been able to raise capital if the bill had passed 10 years ago.

WSJ summarizes: “American drug innovation leads the world, and during the pandemic it has shown its capacity to save millions of lives. It would be a harmful act for the ages against public health if Democrats steal this vital industry’s incentive to produce the cures of the future.”

There’s an old saying, “There’s no such thing as a free lunch.” Add to that, there’s no such thing as new drug innovation without paying the cost of the research.

CDC Credibility Takes Another Hit

It’s been a bad year for the Centers for Disease Control and Prevention (CDC). I first wrote about this in February when new CDC Director Dr. Rochelle Walensky backtracked her recommendations regarding reopening schools without teacher vaccinations after the teachers unions objected. (CDC Credibility Gone) Apparently, the White House let her know she must change her opinion if she wants to keep her job.

Seven months later the CDC is still underwater when it comes to its credibility. Dr. Marty Makary, professor at Johns Hopkins University School of Medicine, tells us in The Wall Street Journal the CDC has failed to provide the information needed to inform a sound Covid strategy. Despite a wealth of data from our own Covid experience, he says the CDC is relying mostly on studies out of Israel to make policy decisions.

The Biden administration can’t rely on CDC studies to justify its booster vaccination plans since they have no studies of their own. Studies from Israel show that a booster resulted in a 10-fold reduction in severe Covid illness in people over 60. The results were published mere weeks after the study’s completion, not months later as often happens in the U.S.

Makary wants to know why the CDC didn’t produce their own research to answer these questions. The agency has 21,000 employees and a $15 billion annual budget. It has data on more than 40 million Americans who have tested positive for Covid and 200 million who have been vaccinated. This data includes vaccine type, dosing schedule, and vaccination date. With this data, calculating the rate of U.S. breakthrough infections and deaths he calls Epidemiology 101.

He also criticizes their lack of vital data on natural immunity – the protection patients receive when they recover from Covid infection. Israel published an important study he calls “powerful and scientifically rigorous” on this subject to date. In a study sample of more than 700,000 people, natural immunity was 27 times more effective than vaccinated immunity in preventing symptomatic infections. Yet U.S. public health officials continue to dismiss natural immunity, insisting that those who have recovered from Covid must still be vaccinated. This opinion is being parroted by the media and other policy makers who are sticking by their original hypothesis that natural immunity is fleeting, even though at least 15 separate studies show it lasts.

Dr. Makary says, “The CDC shouldn’t fish for data to support outdated hypotheses. Heeding the robust Israeli data on natural immunity could help restore the agency’s credibility and even help vaccination efforts.”

There is also important information coming out of Israel regarding vaccinations in children. Researchers found that one dose of Pfizer vaccine, instead of the normal two, was 100% effective in children ages 12 to 15. This is a significant finding since it could have huge implications for achieving broad immunity in adolescents while reducing the risk of heart complications, which have been seen in some after the second dose.

Dr. Makary concludes, “These are the studies U.S. public health agencies should be doing but aren’t. By any metric, the CDC has failed in its primary task of preparing the country for a pandemic and telling us how to reduce harm from the novel Covid pathogen.”

The CDC is our primary health agency whose mission is to accurately inform us on matters concerning our health and the prevention of disease. Sadly, they are failing in this mission and letting politics interfere with good science. In a perfect world, we could rely on them to provide us the most up-to-date scientific research to inform policy makers, but it seems the policy makers are the ones informing the CDC.

Controversy Over Booster Shots

 

Booster shot or not? If you follow this blog regularly, you know I’m in favor of Covid booster shots, especially for the most vulnerable. (Booster Shot or Not? Declining Vaccine Effectiveness) But the Biden administration is giving mixed signals on this important issue.

The CDC came out with recommendations in August to begin a Covid booster shot program beginning September 20th. Much of the data to support this decision comes from studies in Israel, but I also reported a recent study from the University of California San Diego. In response, I got my third Pfizer vaccine booster shot two weeks ago when it was offered to medical staff and their families based on the following eligibility:

  • Age 65 or older
  • Active cancer treatment for tumors or cancers of the blood
  • Organ transplant recipients taking medicine to suppress the immune system
  • Stem cell transplant within the last 2 years or those taking medicine to suppress the immune system
  • Moderate or severe primary immunodeficiency (such as DiGeorge syndrome, Wiskott-Aldrich syndrome)
  • Advanced or untreated HIV infection
  • Active treatment with high-dose corticosteroids or other drugs that may suppress your immune response.

Anyone in any of these categories is at higher risk and adding a third shot increases their protection from infection.

The controversy broke out in today’s media when a group from the U.S. Food and Drug Administration (FDA) as well as the World Health Organization (WHO) objected to the CDC recommendations. In a review article published in The Lancet, a British medical journal that often embroils itself in controversy, these scientists concluded that current vaccine regimens were still very effective at protecting against severe disease from viral variants, including Delta. They prefer using current vaccine supplies to save more lives by vaccinating more of the unvaccinated population. “Even if some gain can ultimately be obtained from boosting, it will not outweigh the benefits of providing initial protection to the unvaccinated,” said Ana-Maria Henao-Restrepo, the study’s leading author and researcher at the WHO.

In other words, these scientists are more concerned with spreading the supply of vaccines around to give initial vaccinations to the unpopulated parts of the world, rather than increasing the protection of the most vulnerable in America. This is not a difference in science; it is a difference of opinion in medical ethics and the setting of priorities. Also, it assumes there is a limited supply of vaccines to go around. With three vaccines approved in the U.S., and at least five others being used world-wide, this is a difficult argument to make.

No one is saying there is evidence it is harmful to get a booster shot. No one is suggesting the booster shots will not increase protection in those who got their initial vaccinations more than six months ago. Some are suggesting the increased number of vaccinations may increase adverse reactions, but there is no proof of that happening.

Support for the booster shots has been widespread apart from this study group published in The Lancet. Robert Wachter, chair of the Department of Medicine at the University of California San Francisco, says there is enough data showing a third dose of the Pfizer vaccine can help protect those who are at risk of worse outcome, such as people over age 60, as well as those at risk of spreading it to vulnerable people, such as nursing home employees and healthcare workers. “If you got Pfizer more than six months ago, as I did, and you’re at more than a moderate risk of a bad outcome if you got infected, I think it’s a pretty clear call,” Dr. Wachter says.

The decision is yours to make – at least at this time! If you’re in a high-risk category, I recommend the booster shot. If you’re not, perhaps you don’t need the extra protection, though it would improve your chances of remaining virus free.

(Note: A panel of FDA advisors has just recommended booster shots for those in the high risk categories, but not for others.)